HIV acquisitions, safety, and pharmacokinetics of lenacapavir for HIV pre-exposure prophylaxis in pregnant and lactating women (PURPOSE 1): a substudy of a phase 3, randomised controlled trial

The Lancet HIV 2026

View at publisher
Authors: Linda-Gail Bekker, Dhayendre Moodley, Dázon Dixon Diallo, Ishana Harkoo, Godfrey Kigozi, Noah Kiwanuka, Cheryl Emily Louw, Moelo Malahleha, Lillian Mworeko, Thesla Palanee-Phillips, Ravindre Panchia, Nishanta Singh
+11 more Sarah B. Puryear, Priyanka Arora, Jared M. Baeten, Andrea Brown, Christoph C Carter, Marjorie Imperial, John Ling, Renu Singh, Pamela Wong, Moupali Das, Flavia Matovu Kiweewa
DOI: 10.1016/s2352-3018(26)00112-8
Cited by: 1
References: 21

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions Cytomegalovirus and herpesvirus research

Publication details

Journal / source
The Lancet HIV
Publisher
Elsevier BV
Volume
13
Issue
9
Pages
e621–e630
Publication date
13 July 2026
Language
EN